These findings highlight the need for further investigation into the combined use of STAT3 inhibitors with immune checkpoint blockade, since STAT3 is directly related to the expression of PDL1 in EGFR-mutant NSCLC [80], as well as in tumors that display chromosomal arrangements of ALK [293,294,295,296]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.